Q3 Earnings Forecast for Immunome Issued By Leerink Partnrs

Key Points

• Equities research analysts at Leerink Partners have revised their Q3 2025 EPS estimate for Immunome, forecasting a loss of ($0.63) per share, an improvement from their previous estimate of ($0.69).
• Immunome's stock has a consensus rating of "Moderate Buy", with eight analysts rating the stock variously as "buy" or "hold", and a price target averaging $23.14.
• Immunome reported a revenue of $4.02 million for the recent quarter, significantly surpassing the consensus estimate of $1.03 million, while earnings per share came in at ($0.50), beating expectations.

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Investment analysts at Leerink Partnrs increased their Q3 2025 earnings estimates for shares of Immunome in a research note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($0.63) for the quarter, up from their previous forecast of ($0.69). The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Leerink Partnrs also issued estimates for Immunome's Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.40) EPS and FY2026 earnings at ($2.66) EPS.

Several other brokerages also recently commented on IMNM. Wedbush reissued an "outperform" rating and issued a $21.00 price target on shares of Immunome in a report on Thursday, August 7th. JPMorgan Chase & Co. decreased their price objective on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Immunome presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.14.

Immunome Stock Performance

Immunome stock traded up $0.09 during mid-day trading on Monday, reaching $10.10. The company's stock had a trading volume of 142,437 shares, compared to its average volume of 1,014,330. The firm's fifty day moving average price is $9.59 and its two-hundred day moving average price is $8.91. Immunome has a 12-month low of $5.15 and a 12-month high of $16.73. The company has a market capitalization of $879.10 million, a P/E ratio of -3.28 and a beta of 1.93.

Immunome (NASDAQ:IMNM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The business had revenue of $4.02 million during the quarter, compared to analyst estimates of $1.03 million.

Insiders Place Their Bets

In other news, Director Jean Jacques Bienaime bought 5,000 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were purchased at an average price of $9.38 per share, for a total transaction of $46,900.00. Following the completion of the purchase, the director owned 36,415 shares in the company, valued at approximately $341,572.70. This represents a 15.92% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 7.69% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. raised its position in Immunome by 37.4% in the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company's stock worth $50,843,000 after acquiring an additional 2,054,640 shares during the period. Redmile Group LLC lifted its holdings in shares of Immunome by 11.0% in the 1st quarter. Redmile Group LLC now owns 5,361,187 shares of the company's stock worth $36,081,000 after acquiring an additional 533,161 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Immunome by 43.4% in the 1st quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company's stock worth $28,987,000 after acquiring an additional 1,303,753 shares during the last quarter. EcoR1 Capital LLC lifted its holdings in Immunome by 5.2% during the 1st quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company's stock valued at $27,454,000 after buying an additional 200,000 shares in the last quarter. Finally, Enavate Sciences GP LLC purchased a new position in Immunome during the 4th quarter valued at about $36,939,000. Institutional investors own 44.58% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.